Get started

Biotech

$VKTX is about to FEAST! Don't miss out on this BioTech trade. 🚀 Here it is: Your Free Saturday Setup! 🚀 Just as promised, here is a detailed video analysis on NASDAQ:VKTX Viking Therapeutics! 🧬 This trade meets all the criteria of my "High Five Setup" trading strategy, backed by solid technical analysis. Also, it has the potential to return over 100% on your capital deployed. With more probabilities on our side, the likelihood of success is through the roof! 📈💥 Check it out, and let’s ride this wave together! 🌊 Stay tuned for more insights! 🔔 NFA #Trading #StockMarket #Biotech #Investing #HighFiveSetup
NASDAQ:VKTXLong
by RonnieV29
41
Prescription for Gains!Recursion Pharmaceuticals is building strong bullish momentum, with a gap forming around the $6.00 level. A breakout above the $8.16 resistance would confirm further upside, targeting the $9.99 weekly resistance. This setup provides an attractive risk-to-reward ratio, with downside managed through a stop-loss at $5.49. In the longer term, RXRX could extend its bullish run to $15.72, supported by the company’s innovative approach to drug discovery using AI and machine learning. As Recursion leverages technology to streamline the development of new therapies, it has positioned itself as a leader in biotech innovation. The increased adoption of AI in healthcare and RXRX’s strategic partnerships further support its potential for strong revenue growth and long-term value. With both technical momentum and a compelling growth narrative in biotech, RXRX is well-positioned to reach $9.99 in the near term, with an eye on $15.72 as a longer-term target. NASDAQ:RXRX
NASDAQ:RXRXLong
by The_Trading_Mechanic
1
Argenx (ARGX) AnalysisCompany Overview: Argenx NASDAQ:ARGX is making significant strides in the field of autoimmune treatments, especially following the FDA approval of VYVGART Hytrulo for chronic inflammatory demyelinating polyneuropathy (CIDP) on June 21st. This approval not only enhances Argenx's product portfolio but also opens up new revenue channels for the company. Key Developments: Strong Revenue Generation: Argenx demonstrates a robust global presence with revenue streams across various regions: U.S.: $407 million Japan: $20 million EMEA: $35 million China: $14 million This diversified revenue generation helps mitigate regional risks and showcases the company’s ability to penetrate multiple markets effectively. Upcoming Trials: The company plans to launch four new registration trials by the end of 2024, further expanding its therapeutic offerings. This proactive approach to research and development positions Argenx for future growth and diversification in its product line. Strategic Collaboration: Argenx's collaboration with Monarch is aimed at enhancing operational efficiency and customer service. This partnership is expected to boost market penetration and strengthen the company's competitive edge. Investment Outlook: Bullish Outlook: We are bullish on ARGX above the $484.00-$489.00 range, driven by its recent FDA approval, diverse revenue streams, and plans for further clinical expansion. Upside Potential: Our target for Argenx is set at $740.00-$750.00, supported by the company’s strong market presence and growth initiatives. 🚀 ARGX—Pioneering the Future of Autoimmune Treatments. #Biotech #AutoimmuneTherapy #MarketGrowth
NASDAQ:ARGXLong
by Richtv_official
RXRX - BIOTECH SQUEEZE PLAY RXRX - Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Consolidating since April, look left and see the explosive moves. Grab cheap long dated calls and wait for news to come out. Easy R/R. Calls swing 100% on small moves and I've got a good bit cheaply Jan 2025 calls. 9 & 10 dollar strikes. Huge opportunity here to cash in on any news or favorable Earnings Report in a few days. Short squeeze targets 10-12 dollars, manage your own risk. Will be dumping calls on impulsive move. $6 looks to be a strong bottom here, under that for any time other than a flash sale, this trade is invalid, and I won't be holding any calls. NOT INVESTMENT ADVICE. TRADE YOUR PLAN!
NASDAQ:RXRXLong
by mortimerkylej
Thanksgiving Gifts for ALL - RXRX - BIOTECH SQUEEZE PLAYRecursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. Chart looks primed, bounced off 6 dollar range a few times and is peaking out of the downtrend. I fully expect to find support along that trendline and chop until news sends this thing flying. Short squeeze potential here and fibs look like a big move could be in store before Thanksgiving which will line up with news around Earnings time. Holding long dated calls and some shares. Calls dated Jan 2025 or later. 8,9,10 strikes Fibs for targets. LFG!
NASDAQ:RXRXLong
by mortimerkylej
ATAI Life Sciences | ATAI | Long at $1.30ATAI Life Sciences NASDAQ:ATAI , a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, is fast approaching my selected historical simple moving average (SMA). Often, but not always, the closer the price gets to this line, the higher chance there is for a fast upward move. In anticipation of this move, NASDAQ:ATAI is in a personal buy zone at $1.30. A word of caution: this is a pure technical analysis play and this company is not expected to be profitable for many, many years... Target #1 = $1.75 Target #2 = $2.50 Target #3 = $2.95
NASDAQ:ATAILong
by NicksAnalysis
Protagonist Therapeutics (PTGX) AnalysisMarket Position and Growth Drivers: Protagonist Therapeutics NASDAQ:PTGX is poised for substantial growth, with its recent inclusion in the S&P Small Cap 600 likely attracting significant institutional buying and boosting its stock price. Strategic Partnership: The company's partnership with Takeda to develop and market Rusfertide has already resulted in a $300 million upfront payment. Promising Phase II trial results for Rusfertide could lead to substantial profits through opt-out payments, milestone payments, and royalties. Investment Outlook: Bullish Outlook: We are bullish on PTGX above the $31.50-$32.00 range. Upside Potential: With an upside target set at $48.00-$50.00, investors should consider Protagonist Therapeutics' strategic partnership and promising clinical results as key drivers for future stock appreciation. 📊🔬 Monitor Protagonist Therapeutics for promising investment opportunities! #PTGX #Biotech 📈🔍
NASDAQ:PTGXLong
by Richtv_official
Twist Biosciences (TWST) AnalysisInnovation and Market Leadership: Twist Biosciences NASDAQ:TWST , a leader in synthetic DNA products, is set for substantial growth with its new Express Genes service, offering NGS-verified genes in just five to seven business days. This innovation is expected to strengthen Twist's market position and dominance. Growth Forecast and Market Expansion: The company forecasts a CAGR of over 28% through 2025, backed by a customer base of over 3,300 across various industries. Targeting multiple large addressable markets, Twist aims to sustain revenue growth for the foreseeable future. Investment Outlook: Bullish Outlook: We are bullish on TWST above the $41.00-$42.00 range. Upside Potential: With an upside target set at $76.00-$78.00, investors should consider Twist's innovative service offerings and robust growth projections as key drivers for potential stock appreciation. 📊🧬 Monitor Twist Biosciences for promising investment opportunities! #TWST #SyntheticDNA 📈🔍
NASDAQ:TWSTLong
by Richtv_official
SIGA Technologies Analysis 6/24Disclosure: As of 6/24 I am long SIGA Technologies NASDAQ:SIGA SIGA Technologies is a bio pharmaceuticals company that is in the public health market. They develop and sell products to treat Smallpox, Ebola, and other public health threats. Management Effectiveness: The company has been consistently profitable since 2018, with margins averaging 30%-40% in recent years with only a few unprofitable quarters. Very quickly after the company became profitable they brought the debt to essentially nothing. In recent years the company's return on equity has been above 25%, indicating their research spending is used effectively. The company has a large cash position for potential investment in research. Valuation The company trade at a P/E of 6 and a p/cf of 8 they have paid special dividends for several years and could potentially implement a stock buyback program, at least that is something I would be considering if I were a board member (Disclosure: I am not a board member obviously). Summary NASDAQ:SIGA is a well run company, trading at an excellent valuation if you are willing to take the risk of a concentrated portfolio of products and volatile returns. They have several positive tailwinds including: International Expansion, Re-Valuation of the company due to implementation of a dividend or buyback policy, and increased public health awareness by international governments.
NASDAQ:SIGALong
by sihen999
4
Roche Analysis 6/26DISCLOSURE: as of 6/26 I have no open position in SIX:RO Roche is a Swiss based pharmaceutical conglomerate with a diverse range of operations and brands. The company has a long history of profitability and high returns on investment. Management Effectiveness: Roche has been around since 1896 and has had consistent growth over the economic cycles. Return on equity has been averaging 40% and although margins have compressed in recent years the company remains highly profitable and in a stable leverage position. Valuation: With a price to earnings of 20 and price to cash flow of 15 if looks potentially undervalued. I like companies that have a return on equity double that of the price to earnings, and that rule of thumb is met in this case. Summary: Roche looks like a quality company to potentially take some profits and diversify from my NASDAQ:SIGA position. However, for now it will stay on the watch list. I will be looking at OANDA:USDCHF as well as the valuation metrics I mentioned above. Here on my macroeconomic and current research shortlist watchlists: www.tradingview.com www.tradingview.com Thanks for reading, have a good one
SIX:RO
by sihen999
Nurix Therapeutics (NRIX) Analysis Clinical Milestone: Nurix Therapeutics NASDAQ:NRIX , a clinical-stage biotech company, achieved a significant milestone with its NX-5948 leukemia drug, showing a 69.2% positive response in a trial for relapsed or refractory chronic lymphocytic leukemia (CLL). Needham analyst Gil Blum praised these results as a "clear win." Strategic Collaborations: Nurix is also advancing collaborations with major pharma companies. It is set to nominate a development candidate with Sanofi this year, positioning it for substantial breakthroughs. Additionally, Gilead Sciences extended its research collaboration with Nurix by two years, highlighting Nurix's robust R&D capabilities. Investment Outlook: Bullish Outlook: We are bullish on NRIX above the $15.00-$16.00 range. Upside Potential: With a target set at $30.00-$31.00, investors should consider Nurix's promising clinical results and strategic partnerships as key drivers for potential stock growth. 📊🧬 Monitor Nurix Therapeutics for promising investment opportunities! #NRIX #Biotech 📈💊
NASDAQ:NRIXLong
by Richtv_official
XBI biotech ETF EW count optionsSharing an intermediate view of the EW count options for XBI. The short-term bullish range is $97-$98. The short-term bearish target ranges are $89 - $88.50 and $87. The bearish count, in red, drops the price to $81ish as first support. If, $81 range does not hold, $72 is the C wave target. In the meantime, I anticipate a lot of chop in the range from $86 - $100 in the next couple months until a rate cut occurs. As speculation of a rate cut increases, the price can begin to gravitate toward $104. When an interest rate cut is proposed, XBI will blast to the $140s but I am reserved about this outcome at this time.
AMEX:XBI
by MontBel
1
Dark Pools Accumulating Biotech: STOKDark Pools are accumulating some biotechnology stocks for mutual funds and ETFs based on this new technology. HFTs are chasing this accumulation. NASDAQ:STOK is now near the price when more professional traders are likely to swing trade. It has a very high Percentage of Shares Held by Institutions and the bottom is completed. It may be a potential candidate for a watchlist for this industry, IF the industry fits your needs for short-term trading or long-term investing. It may also turn into a position trade if platforms develop. This is a Weekly Chart so all the history of recent price is visible. The peaks of bounces upward within the downtrend are where the stock may stall and go sideways as it moves up.
NASDAQ:STOK
by MarthaStokesCMT-TechniTrader
GEVO - The Sleeping Nephilim Giant Alarm Triggered (BIOFUELS)GEVO is priming for a big comeback. It's a sleeping giant. Has been on a down trend close to 2 decades. For pennies on the dollar, this is an opportunity equivalent to mining bitcoin in 2009 and holding your bag for a very long time. This is a long-term hold. 5+ years. Someone believed in the Biofuels technology at one point where a share was traded over $200k. Now it is the time, with government support and incentives... meaning us the people will basically fund this. It's pretty evident that everything is pointing to 'Going Green' with the global warming agenda. The way I see it, is if a carbon tax is implemented, and SAF Net Zero fuels comply with the fuel regulations on the 'carbon footprint' and it is exempt from taxation... well wouldn't all airlines look to supply their airplanes with SAF net zero fuel? As well as GEVO getting government incentives for clean biofuels? Any whom the main agenda is to have everything operating with SAF by 2050. On the Technical side... Basic indicators like MacD and RSI are the most bullish I have ever seen in any chart in any time frame. The picture is clear, the white forecast candles are for goofin' only. Although it relies on the summit carbon solutions pipeline project, if all goes as planned it should start by 2025, where I am confident GEVO will also break ground shortly after EOY 2026. This is where it should be trading at a key point to what the chart is printing. Production of SAF sometime in 2028 and more funding for a larger expansion to just take this back to it's previous years.
NASDAQ:GEVOLong
by jovani7919
1
ATAI - 2 potential paths to $5After successfully surpassing the previous swing high with considerable volume, attaining a fresh 52-week peak of $2.85, and witnessing the 50-day moving averages intersecting the 150 and 200 SMAs, ATAI appears poised for a reversal from its downtrend. **Potential Scenarios:** **Scenario 1: Triangular Consolidation (Orange)** ATAI may undergo consolidation within a triangular pattern marked by points A to E. This consolidation phase could indicate a period of indecision in the market as buyers and sellers balance their positions. Typically, triangular patterns suggest that volatility is decreasing, leading to an impending breakout. If this pattern unfolds as expected, a breakout is anticipated around mid-August, potentially triggering a significant move in the stock price. **Scenario 2: Corrective Pattern (Yellow)** Alternatively, the stock might experience a corrective phase represented by an A-B-C pattern. This corrective pattern could indicate a temporary pullback or retracement within the broader uptrend. Such corrections often serve to alleviate overbought conditions and provide an opportunity for new buyers to enter the market. In this scenario, ATAI is expected to establish a higher low by mid-August, reinforcing the bullish momentum and setting the stage for further upside potential. **Price Targets:** Anticipated Fibonacci targets include 1.414 ($4.45) or 1.616 ($5.54) to be achieved by year-end. These Fibonacci extensions are commonly used by traders to identify potential levels of resistance or support based on previous price movements. Additionally, a more ambitious target exceeding $15 within the next few years is also envisaged. This long-term target reflects the potential for ATAI to capitalize on emerging trends and developments within its industry, driving sustained growth and shareholder value over time.
NASDAQ:ATAILong
by joshuashepherd877
2
Gilead Sciences (GILD): Chances in Pharma Beyond TechGilead Sciences (GILD): NASDAQ:GILD We're aiming to diversify our portfolio beyond just tech stocks and the tech sector. We're now focusing on companies in the pharmaceutical industry, such as Gilead Sciences. Analyzing the weekly chart, we observed the largest surge since 2010 for Wave (3). We believe we've also completed Wave (4) at $56.56. The peak was at $123.27, marking our all-time high. This figure is our target for the minimum achievement for Wave 3. It's crucial, and significantly, we anticipate a high selling pressure at this level. Zooming in, we presume we are in Wave 2, expected to conclude between 61.8% and 78.6% retracement. This positions us with a relatively favorable risk-to-reward ratio on the daily chart. Should we drop below this 78.6% retracement level, we could fall back to $56. If that happens, we'll face a problem, potentially falling further for Wave (4) to a maximum of $30. If this decline doesn't materialize, we'll continue to anticipate an upward movement.
NASDAQ:GILDLong
by freeguy_by_wmc
1
Hold it like a rock - Roche, what an opportunity.Hi, 1PERCENT here. Roche Holding, a Swiss multinational biopharma company. It is like the Apple of biopharma. There were only 3 pull backs greater than 30% in the history of the stock. 2002 ~ 2003: -45.33% 2006 ~ 2011: -52.40% 2014 ~ 2018: -30.24% 2022 ~ present: -44.89% It is at the support zone that initiated the +95% move up from 2018 to 2022, and also is testing the trendline connecting the lows in 2003 and 2011. If you live in the US, you might want to have some exposure to Swiss assets (CHF or stocks) and Gold & silver. The US dollar is losing value against the Swiss Francs in the long term. Otherwise, Roche stock price must hold up at the current support zone , otherwise, we are open for a 30+% drop to the next support zone, which will be of course, an absolute bargain. Also, it looks like the previous turnovers from the lows were always accompanied by the MA36 and MA12 crossing (MA12 over MA36) However, we do not have it here yet. So, let's keep an eye on it. That's it. 1PERCENT
SIX:ROGLong
by RVD_1PERCENT
Pfizer (PFE): Shocking Downward Spiral - $11 Target In Sight?Pfizer (PFE): NYSE:PFE At Pfizer, we believe that Wave (2) has not yet completed because Wave B precisely hits the 138% level and structurally does not make sense unless we see a breakthrough of the invalidation zone of the potential subordinate Wave (i) at about $41.62. However, we must form at least a double bottom at $11, which is our minimum expectation for Pfizer. For the downward movement, we need to examine more closely how far it can actually fall, but $11 is our minimum expectation. The only scenario that would make sense here might be a short position for a possible subordinate Wave (iv) between $36.9 and $41.62. Subsequently, for the overarching Wave ((iii)), we expect another decline to a minimum of $22.64 and, in our opinion, a maximum of $9.56. Entering a long position could be too risky over a longer period. For those looking to trade in the short term, there might be a bottom at $25.61, leading up to the potential target zone for Wave (iv). After that, we expect the downtrend to continue, and personally, we are not positioning ourselves long due to the significant risk.
NYSE:PFEShort
by freeguy_by_wmc